{"id":"NCT00425100","sponsor":"Pfizer","briefTitle":"A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients","officialTitle":"A 12-Week, Multicenter, Open-Label, Single-Arm Study To Evaluate The Effects Of Fesoterodine On Treatment Satisfaction And Symptom Relief In Overactive Bladder Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2007-10","completion":"2007-10","firstPosted":"2007-01-22","resultsPosted":"2009-02-10","lastUpdate":"2018-12-05"},"enrollment":516,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"fesoterodine fumarate","otherNames":[]}],"arms":[{"label":"Open Label-fesoterodine","type":"EXPERIMENTAL"}],"summary":"To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.","primaryOutcome":{"measure":"Mean Number of Micturition Episodes Per 24 Hours","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Open Label Baseline","deltaMin":12.7,"sd":3.9},{"arm":"Open Label Week 12","deltaMin":9.7,"sd":3.4}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":60,"countries":["United States","Belgium","Costa Rica","Czechia","Germany","Poland","Slovakia","South Korea","Ukraine"]},"refs":{"pmids":["19348029"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221007&StudyName=A%20Clinical%20Trial%20To%20Assess%20Fesoterodine%20On%20Treatment%20Satisfaction%20And%20Symptom%20Improvement%20In%20Overactive%20Bladder%20Patients"]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}